Hepatocellular carcinoma (Q29616359)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

Llovet JM

0 references

Forner A

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

Bruix J

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

31 March 2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

volume

379

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

issue

9822

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

page(s)

1245-55

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Coffee drinking and hepatocellular carcinoma: an update.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatocellular carcinoma pathogenesis: from genes to environment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Genomics and signaling pathways in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

MicroRNA expression, survival, and response to interferon in liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Pivotal role of mTOR signaling in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

mTOR and P70 S6 kinase expression in primary liver neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Angiogenesis in liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Principles of cancer screening: lessons from history and study design issues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Randomized controlled trial of screening for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Optimization of imaging diagnosis of 1–2cm hepatocellular carcinoma: An analysis of diagnostic performance and resource utilization

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Current strategy for staging and treatment: the BCLC update and future prospects.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

The evolving role of radiation therapy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Resection and liver transplantation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Waiting list removal rates among patients with chronic and malignant liver diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A model to predict survival in patients with end-stage liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Liver transplantation in patients with hepatocellular carcinoma across Milan criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Loco-regional treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

NCCN clinical practice guidelines in oncology: hepatobiliary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961347-0

7 January 2021

10.1016/S0140-6736(11)61347-0

Identifiers

DOI

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

30 April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=22353262

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017